TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Bone density and structural quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic Specificity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Baseline IC-GREEN elimination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain Change in 24 Hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in glycated haemoglobin (HbA1C, %)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Fugl-Meyer Assessment of Motor Recovery after Stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Respiratory Outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change of weekly physical activity levels
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change of sitting time
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Modified Lobene Stain Index (MLSI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Absolute change in lymphocyte subset counts
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to extract the gall bladder
Endpoint domain: Surgical and medical procedures outcomes
Primary endpoint: fMRI responses to food cues
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Calcium Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Inflammatory Markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: BAY 59-7939 concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: PTT
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Gonadotrophin Secretions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Esophago-gastric junction distensibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Change in pigmentation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Partial and complete response rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: three-year disease free survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Percentage Change in Liver Fat
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Gain in Alveolar ridge width
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants Admitted to Neonatal Intensive Care Unit
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of Participants needed for Mechanical ventilation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With Complete Metabolic Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Anxiety level of patients
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in blood flow (mL/min/100 g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in blood volume (mL/100 g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in mean transit time (seconds)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in permeability (mL/min/100 g)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Depressive symptom count
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: number of hospitalization by heart failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of recurrent stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: number of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Overall platelet response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite post-discharge healthcare use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Disease Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Tolerated Dose (MTD)/Recommended Phase 2 Dose Level (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events Categorized by Severity
Endpoint domain: Adverse events/effects
Primary endpoint: Water diffusion probability density function (FWHM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Water diffusivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lactate Concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Feasibility of MSC knee articular infiltration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of MSC knee articular infiltration
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Patients With Drug-related Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Product usability
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Presence of the internal limiting membrane transposed into foveal region
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants with Major Adverse Cardiac and Cerebrovascular events (MACCE)
Endpoint domain: Adverse events/effects
Primary endpoint: Change in surface area of the scar
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Induction of abnormally fast heart rhythm
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Levels of certain chemicals in blood and urine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Difference in tear film quality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in tear film osmolarity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in conjunctival bulbar redness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Crestal bone resorption
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Neonate Infant Pain Scale Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Muscle Mitochondrial Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of chest compressions and rescue breaths
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoxemic episode
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Normal oxygen saturation values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variability in oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment Success
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: 24-hour urine albuminuria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Rate of inappropriate surgical intervention
Endpoint domain: Adverse events/effects
Primary endpoint: Response rate to PncCV
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Vaccine safety profiles
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of combination mFOLFOX and MK-3475
Endpoint domain: Adverse events/effects
Primary endpoint: Sustained disability worsening
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Percentage of Pre-treatment Images Correctly Identified
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of the CoolSculpting Device in Upper Arm Treatments
Endpoint domain: Adverse events/effects
Primary endpoint: Respiratory drive to hypercapnia measured by P0.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: TAC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MRBA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post-procedural buttock hypoesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of patients with positive detection of IgM and IgG antibodies to SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in Glycosylated Hemoglobin (HbA1C)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Angle at Initial Contact
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Swing Dorsiflexion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With NAAT 1 Index Test Results for Neisseria Gonorrhoeae in Pharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With NAAT 1 Index Test Results for Neisseria Gonorrhoeae in Rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With NAAT 1 Index Test Results for Chlamydia Trachomatis in Pharynx
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Number of Participants With NAAT 1 Index Test Results for Chlamydia Trachomatis in Rectum
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Changes in clinical status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: In-segment Percent Diameter Stenosis at 8 Months Post-procedure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Major Adverse Cardiac Events (MACE) Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Mental Health Treatment Engagement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Newcastle Pediatric Mitochondrial Disease Scale (NPMDS) Sections 1-3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Qualitative detection of Mycoplasma Pneumoniae
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Maximum Tolerated Dose (MTD) of Ultratrace Iobenguane I 131
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in children's Knowledge, attitude, habit (KAH) scores
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in physiotherapy treatment compliance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Progression-free survival (PFS) in intent-to-treat (ITT) population
Endpoint domain: Mortality/survival
Primary endpoint: PFS in PD-L1-selected population
Endpoint domain: Mortality/survival
Primary endpoint: Total Body Clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Volume of Central Compartment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with the Course
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Enactment of Learned Skills
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Six-minutes-walk-test walking distance (6MWD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Generic health-related quality of life (SF36)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in 24/h systolic blood pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Death from any cause within thirty days of admission
Endpoint domain: Mortality/survival
Primary endpoint: Maximum tolerated dose of LEE011
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Spinal fusion success rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sustained Virologic Response at Week 12 After End of Treatment (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in prescription drug use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment of Chinese Body Constitution & Syndromes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Transversus abdominis muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Lumbar multifidus muscle thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Decreased rate of prescription of warfarin and NSAID
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Percentage of Participants Achieving a 20% Improvement in ACR Criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Percent Change From Baseline in Procollagen Type 1 N Terminal Propeptide (P1NP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Mean Percent Change From Baseline in Urinary N Telopeptide/Urinary Creatinine (uNTx/uCr)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Area Under the Concentration-time Curve of Alteplase in Plasma (AUC0-tz)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum Measured Concentration of Alteplase in Plasma (Cmax)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Airway pressure measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Area under the concentration-time curve from zero time to 168 hours (AUC[0-168h])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Preventable post-operative emergency utilization
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change of adipokine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Percentage of Participants With Antibody Titers of ≥10 1/Dil Against Each Parental Dengue Virus Serotype Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Summary of Geometric Mean Titers (GMTs) of Antibodies Against Each Parental Dengue Virus Serotype Strain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of Participants Reporting a Solicited Injection-site or Systemic Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Weight Gain Velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Pharmacokinetics of dutasteride and tamsulosin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of HGMS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Global Rating Scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive battery performance change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Subject pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analogue Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Reduction in diabetic gastropathy dyspeptic symptom severity score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Proportion of acute RV GE hospitalisations
Endpoint domain: Mortality/survival
Primary endpoint: Effectiveness of Rotarix™ vaccination in preventing RV SGE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Patient radiation exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in scores on Memory Tests
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Symptom Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Total number of HZ cases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Endothelial Cell Count (ECD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed recovery time in pharyngitis patients
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change in GABA Levels in Left Thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in GABA Levels in Left Basal-Ganglia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in GABA Levels in Left Temporal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in GABA Levels in Parieto-Occipital
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Percent Change in GABA Levels in Right Thalamus
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: genetic outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Culture Conversion 24 weeks post treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of T1 Gd+ Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Effectiveness of palliative therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of glycemic variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Grading of liver cirrhosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver outcomes
Primary endpoint: Visual Function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of serious adverse events (SAE)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of adverse events (AE) leading to study discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Area Under the Curve (AUC(0-t)) for Sitagliptin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cmax for Sitagliptin and Metformin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Exhaled Nitric Oxide Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Number of readmissions
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Change in Visual Acuity Letter Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Frequency of APPSPIRE application (app) use
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Feasibility of the tobacco control program
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Completeness with the Percentages of Participants surveyed
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Number of Participants With SAEs and AEs Leading to Discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Evidence of infection as measured by presence of persistent swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of infection as measured by presence of fever
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of infection as measured by presence of recurrent swelling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of infection as measured by presence of erythema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Evidence of infection as measured by presence of purulent discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Length of post-operative critical care stay
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Creatinine clearance post-operative days 3, 14, and nadir
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Limits of stability test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensory integration test score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidences of Clavien-Dindo grade II or higher
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in pain severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: O₂ saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnosis of Hypertensive Disorders of Pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Recruitment (willingness to participate in program)
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Participation rates and attrition
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention